The Journal of Nuclear Medicine最新文献

{"title":"Development and Validation of a 18F-Flortaucipir PET Visual Stratification Method","authors":"Ilke Tunali, Jian Wang, Anupa K. Arora, Min Jung Kim, Sergey Shcherbinin, Michael Pontecorvo, Leonardo Iaccarino","doi":"10.2967/jnumed.124.268700","DOIUrl":"https://doi.org/10.2967/jnumed.124.268700","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268700absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Asphericity in FDG PET Is an Independent Prognostic Parameter Improving Risk Stratification in Patients with Head and Neck Squamous Cell Carcinoma","authors":"Patrick Hausmann, Sebastian Zschaeck, Christian Furth, Pavel Nikulin, Paulina Cegla, Siyer Roohani, Elia Lombardo, Joanna Kazmierska, Nathalie L. Albert, Adrien Holzgreve, Iosif Strouthos, Claus Belka, Guillaume Landry, Witold Cholewinski, Jorg Kotzerke, Michael Baumann, Mechthild Krause, Daniel Zips, Jörg van den Hoff, Frank Hofheinz","doi":"10.2967/jnumed.124.268972","DOIUrl":"https://doi.org/10.2967/jnumed.124.268972","url":null,"abstract":"<p>Tumor asphericity in ¹⁸F-FDG PET is a prognostic marker that has been investigated in small pilot studies of patients with head and neck squamous cell carcinoma (HNSCC). Here, we investigated the prognostic role of asphericity in a large multicenter database of patients with HNSCC treated with primary radiotherapy or chemoradiation and assessed its independent prognostic value. <strong>Methods:</strong> In total, 1,104 patients were included in this analysis. All received pretreatment ¹⁸F-FDG PET scans. Clinical risk factors were evaluated, and quantitative PET parameters SUV_max, metabolic tumor volume (MTV), total lesion glycolysis, and asphericity were calculated. Primary study endpoints were overall survival (OS) and locoregional control (LRC). Uni- and multivariate Cox regression analyses were performed. Additionally, asphericity was combined with the best-established quantitative PET parameter of MTV, and the combinatory approach of using asphericity and MTV was compared with the use of only asphericity or MTV by bootstrap analyses. <strong>Results:</strong> Asphericity showed only a modest correlation with the established PET parameters of MTV, SUV_max, and total lesion glycolysis. On univariate testing asphericity was strongly associated with the outcome of patients (LRC and OS with <em>P</em> &lt; 0.001). In multivariate testing of all imaging parameters that were not highly correlated, both MTV and asphericity showed a significant association with LRC (<em>P</em> &lt; 0.001 for MTV and <em>P</em> = 0.021 for asphericity) and OS (<em>P</em> &lt; 0.001 for MTV and asphericity). Asphericity and MTV were binarized and combined for risk stratification, and the prognostic value of the combination was compared with the prognostic value of individual parameters. Bootstrapping revealed significantly better performance by the combinatory approach when compared with MTV (<em>P</em> = 0.012 for LRC and <em>P</em> &lt; 0.001 for OS) and asphericity with regard to OS (<em>P</em> &lt; 0.001) but not for LRC (<em>P</em> = 0.53). <strong>Conclusion:</strong> We were able to show that asphericity bears independent prognostic value and significantly improves risk stratification when combined with MTV in a comprehensive retrospective cohort of HNSCC patients.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Categories","authors":"Henning Weis, Jasmin Weindler, Katharina Schmidt, Martin Hellmich, Alexander Drzezga, Matthias Schmidt","doi":"10.2967/jnumed.124.269091","DOIUrl":"https://doi.org/10.2967/jnumed.124.269091","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269091absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"183 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143618557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy","authors":"Caroline Foxton, Bradley Waldron, Rikke Veggerby Grønlund, Jaime (Jim) Simón, Bart Cornelissen, Edward O’Neill, Daniel Stevens","doi":"10.2967/jnumed.124.268508","DOIUrl":"https://doi.org/10.2967/jnumed.124.268508","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268508absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]-FDG PET/CT in the Initial Staging of Squamous Cell Cancer of the Anal Canal: Results of a Prospective Multicenter Registry","authors":"Ur Metser, Jelena Lukovic, Aruz Mesci, Pamela MacCrostie, Rosanna Chan, Victor Mak, Lisa Avery, Amit Singnurkar, Deanna L. Langer, Kara Ly, Andres Kohan","doi":"10.2967/jnumed.124.269289","DOIUrl":"https://doi.org/10.2967/jnumed.124.269289","url":null,"abstract":"<p>In patients with squamous cell carcinoma of the anal canal (ACC), disease stage influences treatment plans and determines prognosis. Our purpose was to determine the impact of PET on the initial staging of patients with presumed stages II–IV ACC and to assess the association of disease stage per conventional workup (CW) and PET imaging to patient outcomes. <strong>Methods:</strong> In this multicenter registry, patients with CW stages II–IV ACC or equivocal findings for a specific stage were included. Demographic data and stage according to the American Joint Committee on Cancer (AJCC) version 7 as determined by CW and PET were recorded and compared with overall survival (OS). For patients from 1 of the participating institutions, CW and PET stage according to AJCC versions 7–9 were compared with progression-free survival (PFS) and OS. <strong>Results:</strong> There were 813 patients included. PET upstaged 150 of 531 patients (28.2%) and downstaged 84 of 531 patients (15.8%) and assigned a specific stage to 200 of 232 patients (86.2%) with equivocal findings on CW. Stage IV on PET was predictive of significantly poorer OS (<em>P</em> = 0.005). For the 136 patients with staging according to AJCC versions 7–9, CW stages I–IV per versions 7–9 were not predictive of OS (<em>P</em> = 0.684, 0.329, and 0.083, respectively) or PFS (<em>P</em> = 0.622, 0.606, and 0.115, respectively). However, PET stages I–IV per versions 7–9 were associated with OS (<em>P</em> = 0.037, 0.003, 0.003, respectively) and PFS (<em>P</em> = 0.004, &lt;0.001, &lt;0.001, respectively), with version 9 best discriminating PFS for stages II and III. <strong>Conclusion:</strong> In patients with presumed stages II–IV ACC, PET stage differs in up to 44% from CW. PET assigns a specific stage in most patients with equivocal staging on CW. The PET-derived stage was predictive of PFS and OS. Because of its superior prognostication, PET should be used routinely to stage patients with ACC clinical stage II or above.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Synaptic Density in Aging and Alzheimer Disease with [18F]SynVesT-1","authors":"Joseph Giorgio, David N. Soleimani-Meigooni, Mustafa Janabi, Suzanne L. Baker, Xi Chen, Tyler N. Toueg, Robby Weimer, Bastian Zinnhardt, Ari Green, Gil D. Rabinovici, William J. Jagust","doi":"10.2967/jnumed.124.269005","DOIUrl":"https://doi.org/10.2967/jnumed.124.269005","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269005absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"87 1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects","authors":"Juhani Knuuti, Małgorzata Kobylecka, Seweryn Krajewski, Lukasz Steczek, Karina Gotowicz, Joanna Towpik, Kari Kalliokoski, Tuula Tolvanen, Magdalena Kostkiewicz, Przemysław Kozanecki, Joanna Włostowska, Mirosław Dziuk, Leszek Królicki, Jacek Bil, Piotr J. Slomka, Timothy M. Bateman, Mouaz H. Al-Mallah, Panithaya Chareonthaitawee, Prem Soman, Cezary Kozanecki","doi":"10.2967/jnumed.124.268872","DOIUrl":"https://doi.org/10.2967/jnumed.124.268872","url":null,"abstract":"<p>A first-in-human phase I clinical study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential cardiac PET myocardial perfusion imaging tracer, [¹⁸F]SYN2 (¹⁸F-labeled acridine derivative), in healthy subjects. <strong>Methods:</strong> [¹⁸F]SYN2 intravenous administration with PET imaging was performed on healthy volunteers, and sequential whole-body imaging was performed over 4 h. Blood and urine samples were collected for up to 240 min. Safety follow-up visits took place at 2, 5, and 14 d after the administration. <strong>Results:</strong> Ten subjects (8 women and 2 men) completed all study procedures. The mean age was 38.1 ± 8.8 y, and the mean body mass index was 22.7 ± 3.0 kg/m². The mean administered dose of radioactivity was 258 MBq (range, 246–272 MBq). There were no drug-related adverse events, and the tracer was well tolerated in all subjects. The mean whole-body effective radiation dose for [¹⁸F]SYN2 was 0.0195 mSv/MBq. The tracer was rapidly taken up by the myocardial wall and cleared from plasma, leading to good image quality within minutes of tracer injection. <strong>Conclusion:</strong> On the basis of the safety profile, radiation dosimetry, and biodistribution of [¹⁸F]SYN2, it appears to be a promising agent for clinical PET myocardial perfusion imaging and to warrant further clinical studies.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Fibroinflammatory Activity Shown on 68Ga-FAPI-04 and 18F-FDG PET/CT in the Two Subtypes of IgG4-Related Disease","authors":"Silu Liu, Qingqing Pan, Hongzhe Zhang, Linyi Peng, Wen Zhang, YunLu Feng, Dong Wu, Yaping Luo","doi":"10.2967/jnumed.124.268943","DOIUrl":"https://doi.org/10.2967/jnumed.124.268943","url":null,"abstract":"<p>IgG4-related disease (IgG4-RD) is a highly heterogeneous autoimmune disease. Recently, 2 subtypes of IgG4-RD, proliferative and fibrotic, were defined according to patients’ clinicopathologic characteristics. The purpose of this study was to determine the difference in fibroinflammatory activity shown on ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT in the proliferative and fibrotic IgG4-RD subtypes. <strong>Methods:</strong> Thirty-seven newly diagnosed IgG4-RD patients (29 of the proliferative subtype and 8 of the fibrotic subtype) who had undergone ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT were enrolled. SUV_max and target-to-background ratio (TBR) of IgG4-RD lesions were measured. To evaluate the weight of fibroinflammatory activity, the PET index of a lesion was calculated as the quotient of SUV_max or TBR of ⁶⁸Ga-FAPI-04 and that of ¹⁸F-FDG. For the assessment of the global disease in an individual patient, the PET index was defined as the ratio of SUV_mean of all involved lesions in ⁶⁸Ga-FAPI-04 PET/CT to that in ¹⁸F-FDG. <strong>Results:</strong> The ¹⁸F-FDG uptake values of the most prominent lesions in the proliferative and fibrotic subtypes were similar; however, the proliferative subtype showed significantly higher uptake of ⁶⁸Ga-FAPI-04 than did the fibrotic subtype (SUV_max, 17.67 ± 7.46 vs. 10.93 ± 2.22, <em>P</em> = 0.005; TBR, 15.49 ± 8.23 vs. 9.25 ± 3.00, <em>P</em> = 0.015). The PET index of proliferative-subtype patients was higher than that of fibrotic-subtype patients (1.46 ± 0.41 vs. 1.14 ± 0.39, <em>P</em> = 0.039). The PET index of pancreatobiliary disease was significantly higher than that of head-and-neck disease, fibrosis or aortitis, lymph nodes, and another disease subtype (<em>P</em> &lt; 0.05). After first-line treatment, patients with a PET index of at least 1.5 had significantly shorter relapse-free survival than those with a PET index of less than 1.5 (22.0 mo vs. not reached, <em>P</em> &lt; 0.0001; hazard ratio, 13.46; 95% CI, 2.236–81.03). <strong>Conclusion:</strong> The proliferative subtype of IgG4-RD had a greater weight of fibroinflammatory activity than that of the fibrotic subtype. The PET index, a marker of the weight of fibroinflammatory activity, is predictive of relapse-free survival of IgG4-RD.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"318 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor–04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy","authors":"Rongxi Wang, Jiarou Wang, Jialin Xiang, Huimin Sui, Linlin Li, Chenhao Jia, Xingtong Peng, Xiaoyuan Chen, Zhaohui Zhu, Jingjing Zhang","doi":"10.2967/jnumed.124.268258","DOIUrl":"https://doi.org/10.2967/jnumed.124.268258","url":null,"abstract":"<p>Solitary fibrous tumor (SFT) is a rare sarcoma of mesenchymal origin. Although generally benign, SFTs carry the risk of recurrence and metastasis, with limited effective treatment options. The aims of this study are to compare the performance of fibroblast activation protein inhibitor (FAPI), [⁶⁸Ga]Ga-DOTA-FAPI-04 (denoted as [⁶⁸Ga]Ga-FAPI-04), and conventional [¹⁸F]FDG PET/CT in patients with recurrent or metastatic SFTs head to head and to preliminarily explore the value of FAP-targeted radiopharmaceutical therapy with ¹⁷⁷Lu for SFT patients. <strong>Methods:</strong> Thirty-one participants (21 men, 44 ± 13 y) with suspected recurrent or metastatic SFTs underwent both [¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04 PET/CT within 1 wk. The positive-lesion rates of the 2 PET/CT scans in the different organs involved and the uptake values (SUV_max) were compared. Four patients with high [⁶⁸Ga]Ga-FAPI-04 uptake received single-cycle therapy of 2.22 GBq of a [¹⁷⁷Lu]Lu-labeled, FAP-targeted radiopharmaceutical, [¹⁷⁷Lu]Lu-Evans blue–FAPI, and were followed up for 4 mo. <strong>Results:</strong> In 522 local recurrences and distant metastases in the 31 patients, [⁶⁸Ga]Ga-FAPI-04 PET detected significantly more lesions than did [¹⁸F]FDG (87.0% vs. 45.4%, <em>P</em> &lt; 0.001). In terms of lesion uptake values, [⁶⁸Ga]Ga-FAPI-04 PET showed a mean SUV_max higher than that of [¹⁸F]FDG in most recurrence or metastatic organs (bone, lung, central nervous system, pancreas, and pleura, <em>P</em> &lt; 0.001; kidney and abdominopelvic cavity, <em>P</em> = 0.001; muscle and pericardium, <em>P</em> &lt; 0.05). Four patients tolerated [¹⁷⁷Lu]Lu-Evans blue–FAPI well. The total-body absorbed dose and the effective dose were 4.02E−01 ± 3.54E−02 Gy and 4.01E+02 ± 4.18E+01 mSv, respectively. Subsequent follow-up with [⁶⁸Ga]Ga-FAPI-04 PET showed that these patients were in stable condition. <strong>Conclusion:</strong> [⁶⁸Ga]Ga-FAPI-04 may be a promising PET agent for the assessment of SFTs. Given the lack of effective treatments for advanced SFTs, high FAP expression in this type of tumor is expected to become a potential treatment target.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143570381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total-Body Parametric Imaging Using Relative Patlak Plot","authors":"Siqi Li, Yasser G. Abdelhafez, Lorenzo Nardo, Simon R. Cherry, Ramsey D. Badawi, Guobao Wang","doi":"10.2967/jnumed.124.268496","DOIUrl":"https://doi.org/10.2967/jnumed.124.268496","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268496absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}